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Introduction and objectives. Data on chronic anemia following heart transplantation (HT) are scarce and 
contradictory. Our aims were to determine the prevalence of chronic anemia after HT, to identify predisposing factors 
for the condition at 12 months, and to evaluate its influence on mediumterm and long-term survival. 
Methods. Retrospective analysis of patients who underwent HT between 1991 and 2005 (n=457). Chronic anemia 
was defined as a hemoglobin level <12 g/dL. 
Results. The prevalence of post-HT chronic anemia was 75.5% at 1 month, 31% at 12 months, and 26.2% at 120 
months. The condition was significantly more prevalent among women than men. Predisposing factors for chronic 
anemia 1 year post-HT were mild-to-moderate chronic renal failure (ie, creatinine level > 1.5 mg/dL; odds ratio 
[OR]=2.8; 95% confidence interval [CI], 1.5-5.0), female sex (OR=6.4; 95% CI, 3.1-13.2), and immunosuppression 
with mycophenolate mofetil compared with azathioprine (OR=2.6; 95% CI, 1.4-4.8). The prevalence of chronic 
anemia 12 months after HT was independent of the donor's sex, the recipient's age, the etiology of the recipient's 
heart failure, diabetes mellitus, mild-to-moderate graft rejection, cytomegalovirus infection, and angiotensin-
converting enzyme inhibitor treatment. The presence of chronic anemia 12 months after HT did not influence either 
long-term survival (mean, 11.5 years with chronic anemia vs 13.0 years without) or actuarial survival. 
Conclusions. Post-HT chronic anemia is common, but improves with time and treatment. Predisposing factors for the 
condition 1 year post-HT include chronic renal failure, female sex, and immunosuppression with mycophenolate 
mofetil. The presence of chronic anemia does not appear to influence long-term survival. 
Introducción y objetivos. La información disponible sobre anemia crónica (AC) en pacientes con trasplante cardiaco 
(TC) es escasa y discordante. Nuestro objetivo fue estudiar la prevalencia de AC en pacientes post-TC, factores 
predisponentes de AC a 12 meses y su significa-do pronóstico a medio y largo plazo. 
Métodos. Análisis retrospectivo de pacientes con TC entre 1991 y 2005 (n = 457). AC fue definida como 
hemoglobina < 12 g/dl. 
Resultados. La prevalencia de AC post-TC fue del 75,5% a 1 mes, el 31% a los 12 meses y el 26,2% a los 120 meses, 
significativamente más prevalente en mujeres que en varones. Factores predisponentes de AC a 12 meses: 
insuficiencia renal crónica (IRC) leve-mode-rada (creatinina > 1,5 mg/dl) (odds ratio [OR] = 2,8; intervalo de 
confianza [IC] del 95%, 1,5-5); sexo femenino (OR = 6,4; IC del 95%, 3,1-13,2), e inmunosupresión con 
micofenolato mofetilo (MMF) respecto a azatioprina (OR = 2,6; IC del 95%, 1,4-4,8). La prevalencia de AC 1 año 
tras el TC no se relacionó con el sexo del donante, la edad del receptor, la cardiopatía del receptor, la diabetes 
mellitus, el rechazo leve o moderado del injerto (= 3A), infección por citomegalovirus o tratamiento con inhibidores 
de la enzima de conversión de angiotensina. Tener AC a 1 año del TC no supuso diferencias en la supervivencia a 
largo plazo (tiempo de vida medio con AC, 11,5 años y sin AC, 13 años) ni en la supervivencia actuarial. 
Conclusiones. La AC post-TC es un problema frecuente que mejora con el tiempo y el tratamiento. La IRC, el sexo 
femenino y la inmunosupresión con MMF predisponen a AC a los 12 meses del TC. Tener AC no parece influir en la 
supervivencia a largo plazo. 
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Introduction 
Chronic anemia (CA) is a frequent complication after heart transplantation (HT) and transplantation of 
other solid organs, such as the kidney, liver, or lung.1-4 Its prevalence varies and values between 0%1 and 
91.6% have been reported.5 This enormous discrepancy in the literature may be related to differences in 
the hemoglobin concentrations (Hb) used to define anemia, in the timing of assessing post-HT patient 
evolution, in the immunosuppression regimen used, or in the management of post-HT anemia.  
The etiology of post-HT anemia is not well understood, although it seems to be multifactorial1,5,6; 
suggested causes include immunosuppression (especially antiproliferative agents),7 perioperative 
bleeding, reduced intestinal nutrient absorption (iron, vitamin B12, and folic acid), renal failure with low 
erythropoietin levels8 (due to cardiorenal syndrome in advanced heart failure prior to HT or the 
nephrotoxicity of some immunosuppressive agents, mainly calcineurin inhibitors),9 poor response to 
endogenous erythropoietin, frequent blood sampling, viral infections, and treatment with angiotensin-
converting enzyme inhibitors [ACE inhibitors]). Similarly, these patients often receive chronic treatment 
with antiplatelet agents and, occasionally, anticoagulants, which may at times favor the persistence of 
anemia due to occult bleeding. 
According to Müller et al,6 Hb concentrations in the first year after HT has long-term prognostic 
significance, although this observation has not been reproduced in other studies.5 
Finally, there is no consensus on the treatment and prevention of post-HT anemia, which makes 
management of the condition different in each center and, in general, the approaches employed have been 
extrapolated from studies on the management of anemia in HF or in renal failure.10,11 
The aim of this study was to improve understanding of post-HT CA, analyze the prevalence of anemia 
at discharge and at 1, 3, 6, 12, 24, 60, and 120 months after HT, assess predisposing factors for CA at 1 
year post-HT, and determine its prognostic significance in the medium-term and long-term.  
Methods 
Patients 
A cohort of consecutive patients with HT, admitted to Complejo Hospitalario Universitario Juan 
Canalejo, La Coruña between January 1991 and March 2005 (n=481). The patients were enrolled in the 
cohort on the day of HT, and were followed up until March 2006 or until their death, if this occurred 
before.  
Demographic characteristics are shown in Table 1. Patients less than 16 years (n=24) were excluded.  
Table 1. Demographic Data of the Patients (n=457) 
  
Sex  
Men  383 (83.8%)  
Women  74 (16.2%)  
Age at HT, years  55 (10.74)  
Heart disease prior to HT  
Ischemic  193 (42.2%)  
Idiopathic  188 (41.1%)  
Valvular  45 (9.8%)  
Other  31 (6.8%)  
Baseline immunosuppression  
CsA+AZA+prednisone  234 (51.2%)  
CsA+MMF+prednisone  148 (32.4%)  
CsA+everolimus+prednisone  9 (2%)  
Other  66 (14.4%)  
Creatinine concentration at 1 year, mg/dL  1.45 (0.49)  
Hb at 1 year, mg/dL  12.52 (1.6)  
  
 
AZA indicates azathioprine; CsA, cyclosporine; MMF, mycophenolate 
mofetil; 
HT, heart transplantation. 
  
Hemoglobin 
Hemoglobin concentrations were collected retrospectively at different times post-HT: at discharge and 
at 1, 3, 6, 12, 24, 60, and 120 months after HT. Anemia was defined as Hb <12 g/dL in both men and 
women.8,11 Immediately after the operation, the patients received a transfusion of concentrated red blood 
cells if they presented symptomatic anemia or Hb <6 g/dL.12,13 
Other Laboratory Parameters  
Chronic renal failure (CRF) was considered mild if the serum creatinine concentration was between 
1.5 mg/dL and 2.49 mg/dL, moderate if the serum creatinine concentration was ≥ 2.5 mg/dL without need 
for dialysis or renal transplantation, and severe if the patients required dialysis or renal transplant.9 
Prophylaxis Protocol and Treatment of Cytomegalovirus 
Prophylaxis was given for 4 weeks post-HT, initially with intravenous ganciclovir and subsequently 
with oral valganciclovir. From this point on, patients were monitored using an antigenemia test for 
cytomegalovirus (CMV) and preemptive therapy given according to the protocol described.14 
Immunosuppression 
The baseline immunosuppressive regimen was changed over time. From 1991 to 2000, all the patients 
received induction therapy with muromonab-CD3 (OKT3) (5 mg/day; mean, 4 doses/patient).  
In 2000, some patients received basiliximab (2 doses of 20 mg, days 0 and 4 post-HT), and from 2002 
onwards basiliximab (and occasionally daclizumab) totally replaced OKT3. 
From 1991 until April 1998, cyclosporine (CsA), azathioprine (AZA), and prednisone was used as the 
baseline immunosuppressive regimen. In 1995, mycophenolate mofetil (MMF) was introduced as rescue 
therapy instead of AZA, and in 1998 this replaced AZA as the baseline immunosuppressive regimen. In 
November 1997, tacrolimus was introduced in place of CsA as rescue therapy or due to the adverse 
effects of CsA.15 
Acute rejection episodes (endomyocardial biopsy, ISHLT grade ≥ 3A or 2R16) were treated with a 
bolus of 250 mg to 1 g of methylprednisolone/day for 3 days. If rejection was persistent or involved 
hemodynamic deterioration, OKT3 or thymoglobulin was used. If antibody-mediated rejection occurred 
(humoral), in addition to boluses of steroids, serial plasma exchange was performed and rituximab was 
sometimes administered. 
Other Treatment 
From the immediate post-HT period until blood Hb concentrations were normalized, all the patients 
received prophylaxis and treatment for iron deficiency anemia using 80 mg ferrous sulfate and 350 μg 
folic acid (Tardyferon®). In case of suspected poor absorption of oral iron, having ruled out 
gastrointestinal bleeding and neoplasms, intravenous iron-sucrose (Venofer®) was administered in 
loading and maintenance doses. The patients with anemia and moderate CRF with normal iron 
concentrations (iron, 59-158 μg/dL; ferritin, 30-400 ng/dL; transferrin saturation, 20%-55%) were treated 
with human recombinant erythropoietin or darbepoetin alpha (Aranesp®).7 
The patients were also treated with gastrointestinal protection agents (ranitidine or omeprazole), 
diuretics in case of water retention, antihypertensive agents (ACE inhibitors, angiotensin-II recipient 
antagonists, alpha-blocking agents, calcium channel blockers), aspirin, calcium, vitamin D, and statins 
(pravastatin, atorvastatin, fluvastatin, or simvastatin).  
Statistical Analysis 
Continuous quantitative variables were expressed as mean and standard deviation, and between-group 
comparisons were analyzed using the Student t test. Discrete variables were expressed as percentages, and 
comparisons were assessed using χ2. Hemoglobin values were normally distributed. Conditional logistic 
regression models were used to asses the association between anemia and predisposing factors (donor’s 
and recipient’s age and sex, initial immunosuppressive regimen with AZA compared to MMF, diabetes 
mellitus at 12 months post-HT, incidence of mild or moderate graft rejection [≥ 3A], ACE inhibitor 
therapy, or mild or moderate CRF). The multivariate analysis of survival-related factors was performed 
using Cox proportional hazard model, adjusting for clinically selected variables, such as recipient’s age 
and sex, renal failure, and immunosuppression with AZA compared to MMF.  
Statistical analysis was conducted using the SPSS for Windows statistical software package, version 
14.0 (SPSS, Chicago, Ill., USA). P values <.05 were considered statistically significant. The study was 
conducted in compliance with laws governing the protection of personal data and in line with the 
international recommendations on clinical research according to the Declaration of Helsinki developed by 
the World Medical Association. 
Results 
The mean age of the 457 patients included in the study at the time of HT was 55 (10.7) years; 383 
(83.8%) were men. The underlying heart condition leading to HT was ischemic heart disease in 42.2%, 
idiopathic dilated cardiomyopathy in 41.1%, valvular heart disease in 9.8%, and other in 6.9% (Table 1). 
At the time of HT, 15.3% of the recipients (n=70) were ≥ 65 years old and 32.8% had creatinine 
concentrations ≥ 1.5 mg/dL.  
The following number of Hb values were included in the analysis: 334 at discharge, 339 at 1 month, 
333 at 3 months, 326 at 6 months, 324 at 12 months, 317 at 24 months, 215 at 60 months, and 66 at 120 
months.  
Prevalence of Chronic Anemia 
There was a high prevalence of anemia in the first months post-HT; 90.5% at hospital discharge and 
75.5% 1 month after surgery (Figure 1). During the first year post-HT, the prevalence of CA gradually 
decreased, although more significantly in men than in women, with a statistically significant difference at 
6, 12, 24, and 60 months (33.5% vs 55.2%; 24.9% vs 58.6%; 25.9% vs 49.1%; and 17.8% vs 47.1%, 
respectively). In the late post-HT period, the prevalence of anemia decreased to 20%-30% in men and to 
around 50% in women, 5 years post-HT.  
 
 
 
Figure 1. Mean hemoglobin concentrations after heart transplantation 
  
Differences Between Sexes 
Figure 1 shows that the Hb concentrations in women were lower than those in men from 3 months 
post-HT onward. This difference was statistically significant from 6 months post-HT onward.  
Predisposing Factors for Anemia at 12 Months 
Risk factors for CA were analyzed at 1 year, since, like other authors, we consider this sufficient time 
for confounding factors to balance out during the immediate postoperative period in the post-HT patient.  
The following factors are associated with chronic anemia at 1 year: mild or moderate CRF (CRF was 
present in 53% of the patients with CA vs 35.4% without CA; P =.03); female sex (34% of women with 
CA vs 10.8% without CA; P <.01); recipient’s age (24% of the patients ≥ 65 years with CA vs 13.9% 
without CA; P =.02); and baseline immunosuppression with MMF (67% of the patients with MMF and 
CA vs 55.2% without CA; P =.04) (Table 2).  
Table 2. Predisposing Factors for Anemia at 12 Months 
 Without Anemia (n=223) Anemia (n=100) P 
    
Recipient’s age, mean (SD), years  54.53 (10.77) 56.26 (10.62) .18 
Donor’s age, mean (SD), years  35.53 (12.60) 34.3 (13.23) .42 
Female recipient  24 (10.8) 34 (34) <.01 
Female donor  55 (24.7) 25 (25) .94 
Baseline immunosuppression AZA  100 (44.8) 3 (33) .04 
Baseline immunosuppression MMF  123 (55.2) 67 (67) .04 
DM in recipient at 1 year  77 (34.5) 38 (38) .54 
Renal failure in recipient at 1 year  79 (35.4) 53 (53) .03 
Cytomegalovirus at 1 year  103 (46.4) 52 (52) .31 
History of rejection  119 (53.4) 63 (63) .10 
Heart disease in the recipient   NS 
Idiopathic  96 (43) 49 (49)  
Ischemic  96 (43) 37 (37)  
Valvular  21 (9.4) 9 (9)  
Other  10 (4.5) 5 (5)  
ACEi 1 year  53 (25.5) 20 (20) .51 
Recipient’s age >65 years  31 (13.9) 24 (24) .02 
    
 
AZA indicates azathioprine; DM, diabetes mellitus; ACEi inhibitors, angiotensin-converting enzyme inhibitors; MMF, 
mycophenolate mofetil.  
The variables presented in Table 2 were included in a logistic regression analysis to confirm 
independent predictors of CA at 12 months post-HT. The following independent predictors were 
identified: mild or moderate CRF (OR=2.8; 95% confidence interval [CI], 1.5-5; P =.01); female sex 
(OR=6.4; 95% CI, 3.1-13.2; P ≥ .01); and baseline immunosuppression with MMF compared to AZA 
(OR=2.6; 95% CI, 1.4-4.8; P =.03). 
The prevalence of anemia at 12 months post-HT was independent of donor’s sex, recipient’s age, the 
etiology of the recipient’s heart disease, diabetes mellitus at 12 months post-HT, the incidence of mild or 
moderate graft rejection (≥ 3A), CMV infection in the first year post-HT, and ACE inhibitor therapy.  
Survival 
Mean follow-up time in our cohort was 5.2 (4) years. Mean long-term survival was 12.3 years; 11.5 
years in patients with CA versus 13 years in those without CA (nonsignificant difference). Chronic 
anemia at 1 year post-HT was not associated with differences in long-term survival. Survival in patients 
with CA versus those without CA at 24, 60, and 120 months post-HT was 93% versus 94%, 84% versus 
86%, and 58% versus 73%, respectively (P =.66) (Figure 2). Cox proportional hazard regression showed 
that there was no association between any of the risk factors mentioned and medium-term and long-term 
survival.  
  
 
 
 
Figure 2. Kaplan-Meier curves for survival by presence of anemia 1 year post-heart 
transplantation.  
Discussion 
The general prevalence of CA in our series of 457 patients was 30% in the first year post-HT. This 
value was greater in women (58.6% in women vs 24.9% in men). Prevalence was very high in the first 
month post-HT (75.5%) and gradually decreased after replacement therapy with ferrous sulfate and folic 
acid. Risk factors for anemia at 1 year post-HT was female sex, renal failure or immunosuppressive 
regimen (MMF vs AZA).  
Prevalence 
The prevalence of post-HT anemia in our series differs from that reported in other series, which may 
be due to differences in the timing of assessing post-HT chronic anemia, and the Hb values used to define 
anemia. We defined anemia as Hb <12 g/dL, in line with other studies,8,11 one of which was conducted in 
Spain.11 
In 1992, Hunt et al1 reported a prevalence of post-HT anemia of 0% at 6, 12, 18, 24, and 36 months, 
which is a strikingly different value from that described in current publications, although these authors 
defined anemia as Hb ≤ 10 g/dL, which underestimates the diagnosis of mild and moderate anemia. Their 
study reported that women presented lower Hb concentrations, which is in line with our results.  
Müller et al6 defined anemia as Hb <14 g/dL and reported a prevalence of 72%. They measured Hb 
concentrations intermittently during the first year post-HT, using the lowest value for each patient, unlike 
our study, in which consecutive measurements were made during the post-HT period.  
In 2004, Gleissner et al5 reported a prevalence of anemia of 91.6%, by calculating the average Hb 
values between 7 months and 12 months and defining anemia as Hb <14 g/dL in men and <13.5 g/dL in 
women. As this involved averaging the results rather than analyzing the values at different post-HT 
periods, their results are not comparable to ours.  
Taking the foregoing into account, it is difficult to compare the different studies on prevalence of 
anemia in patients with HT, as well as the fact that the samples were small in these series (99 patients, 
Hunt et al,1 60, Müller et al, 6 and 156, Gleissner et al5). 
  
Risk Factors and Treatment  
Our finding that post-HT renal failure is a risk factor for post-HT anemia agrees with the findings of 
Gleissner et al5, who also found a highly significant correlation between Hb concentrations and creatinine 
clearance estimated by the Cockroft-Gault formula.  
Renal failure is a frequent post-HT complication with multifactorial etiology that basically includes 
cardiorenal anemia syndrome17 in the patient with terminal heart failure waiting for HT, as well as post-
HT renal damage (cardiopulmonary bypass and immunosuppressive regimen).  
Female sex is a known risk factor for anemia in other diseases such as heart failure18,19 ; Hunt et al1 
observed lower Hb concentrations in post-HT women.  
However, female sex has never been reported as an independent risk factor for post-HT anemia. This 
may be due to the fact that women only form between 20% and 30% of these cohorts.  
On the other hand, by adopting a single Hb value to define anemia in both women and men, the 
percentage of women with anemia increased in our cohort, and reached statistical significance 12 months 
post-HT.  
It should be emphasized that female sex is also a risk factor for anemia in patients who have 
undergone kidney transplantation.20,21 
Our finding that treatment with MMF versus AZA is an independent risk factor for anemia at 1 year 
does not agree with reports from other studies. In the only multicenter randomized study comparing MMF 
with AZA in HT, Eisen et al22 and Kobashigawa et al23 found no significant differences in Hb 
concentrations at 1-year follow-up or 3-year follow-up. Nevertheless, in this study only 50% of the 
patients continued with the assigned medication (MMF or AZA) to the end of follow-up.  
Although a study comparing AZA and MMF in patients undergoing renal transplantation without graft 
dysfunction found that MMF was associated with greater Hb concentrations at 6 months,24 other studies 
are in agreement with our finding regarding an association between MMF and anemia.21,25 
Vanrenterghem et al25 remarked on the unexpected association between MMF and anemia, since 
MMF is not known to have an antiproliferative effect on bone marrow except in lymphopoiesis.26 
In regard to renal transplantation patients, Shah et al,21 reported an association between graft 
dysfunction, change in immunosuppressive regimen to MMF, and anemia, although the real causal 
association would be graft dysfunction and anemia.  
In a recent metaanalysis of 20 studies that included 6387 renal transplantation patients treated with 
MMF, Wang et al27 did not find a statistically significant difference between subjects treated with 2 g/day 
or 3 g/day MMF, or any dose of AZA in the development of anemia. 
Finally, our findings are based on a nonrandomized study, and thus should be confirmed by other 
studies.  
Treatment 
In the first months post-HT, iron deficiency anemia, due to bleeding and undernutrition during the 
perioperative period, is easily corrected with replacement therapy (oral iron and folic acid). In fact, only 
31% of our patients had anemia 1 year post-HT. Other disorders have to be ruled out in these patients 
(such as gastrointestinal bleeding or neoplasms) and individualized treatment given. In case of iron 
deficiency anemia resistant to oral iron, as occurs in chronic renal failure patients not on dialysis, 
intravenous iron can be useful.28 
Survival 
Chronic anemia has been demonstrated as a risk factor for mortality in several cardiovascular diseases, 
especially in heart failure.18,19,29-31 However, in our series, post-HT CA did not appear to influence 
survival, which is in line with the findings of Gleissner et al.5 Thus, it could be said that the prognostic 
significance of anemia in heart failure is lost after heart transplantation; anemia remains a frequent 
postsurgical complication, but responds well to replacement therapy in most cases.  
Limitations 
Although not the aim of this study, we did not measure serum erythropoietin concentrations nor were 
data recorded on iron concentrations, red blood cell morphology, or bone marrow aspiration, and thus our 
observations regarding etiology remain merely speculative. Neither did we define anemia using different 
Hb values for men and women, unlike other authors.   
Conclusions 
Chronic anemia in HT patients is a very frequent problem in the postoperative period and at discharge, 
but decreases over time with appropriate treatment. Female sex, immunosuppressive regimen with MMF 
versus AZA, and renal failure are predisposing factors for anemia 1 year post-HT. The presence of 
anemia 1 year post-HT does not seem to influence long-term survival.  
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